Metastatic choriocarcinoma during normal pregnancy presenting as thyroid tumor

A. Eriksson,C. Gezelius

DOI: https://doi.org/10.1007/BF02134008

Archives of Gynecology

Abstract:

What problem does this paper attempt to address?

From strict quarantine to an optimized policy: Are we psychologically prepared?

Jian-Bo Lai,Ling-Zhuo Kong,Jun Chen,Shao-Hua Hu

DOI: https://doi.org/10.1016/j.ajp.2022.103435

IF: 13.89

2022-01-01

Asian Journal of Psychiatry

Abstract:Few studies have examined the clozapine in cohort studies of Chinese patients with schizophrenia in rural primary care. The objective of this two-year cohort study was to describe the usage of clozapine and investigate and identify the demographic, clinical correlations and risk variables which affect the use of clozapine in patients with schizophrenia. A random cluster sampling technique was used, and participants were collected from China National Psychiatric Management System (CNPMS). The variables for clozapine use in individuals with schizophrenia who had undergone a two-year follow-up were determined using the generalized estimating equation (GEE). In this study, 742 patients with schizophrenia were invited, and 491 completed the two-year follow-up study. Being married, more years of education, more waist circumference, using mood stabilizer, using anticholinergic, higher ITAQ (Insight and Treatment Attitude Questionnaire) scores were more significantly related to the use of clozapine. Older age of onset, using second-generation antipsychotics (SGAs) except clozapine predicted a lower prevalence of using clozapine. The usage of clozapine was very common in patients with schizophrenia treated by primary care physicians, and was influenced by a variety of factors, including price of drugs, clinical factors, health regulations, and the characteristics of treatment environment. Further examination of the rationale and appropriateness of clozapine in primary care in China is necessary.
Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine

Kohei Kitagawa,Shusuke Uekusa,Yuki Hanai,Itsuki Kimura,Masaru Tsukahara,Azusa Kagawa,Kenji Sasaoka,Yui Sakishiro,Ayaka Miyake,Yuki Watanabe,Daiki Baba,Masafumi Kodama,Yoshiki Kishi,Norihito Yamada,Takashi Yoshio,Kazuhiro Matsuo

DOI: https://doi.org/10.1016/j.ajp.2024.104047

IF: 13.89

2024-04-11

Asian Journal of Psychiatry

Abstract:Psychopharmacotherapy for patients with schizophrenia in Japan has a long history of polypharmacy, which is rare worldwide but remains a critical problem. One reason for this is that clozapine was not available in Japan until 2009. We aimed to investigate the changes in psychopharmacotherapy in patients with schizophrenia over 12 years pre- and post-introduction of clozapine to clarify how psychopharmacotherapy for patients with schizophrenia has changed with the introduction of clozapine. We retrospectively collected data from the medical records of inpatients diagnosed with schizophrenia at the Okayama Psychiatric Medical Center. Chlorpromazine equivalent (CP-eq) decreased from 1276.6 mg/day in 2009 to 613.9 mg/day in 2020. The prescribed daily dose/defined daily dose (PDD/DDD) decreased from 3.0 in 2009 to 1.2 in 2020. The monotherapy rate increased from 24.4% in 2009 to 74.6% in 2020. Our institution began using clozapine in 2010, and the prescription rate for clozapine increased to 37.3% in 2020. The prescription rate for more than three antipsychotics decreased from 27.8% in 2009 to 0.8% in 2020. The increase in clozapine prescription has contributed to an increased rate of antipsychotic monotherapy and a decreased rate of polypharmacy, promoting the optimization of schizophrenia medication. Clozapine therapy should be further promoted in Japan to reduce treatment-resistant schizophrenia due to polypharmacy as much as possible.

psychiatry
Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic

Helen Thai,Nicholas Preobrazenski,TiChen Hsieh,Carrie Robertson,Olabisi Owoeye

DOI: https://doi.org/10.1093/schbul/sbae113

2024-07-10

Schizophrenia Bulletin

Abstract:Abstract Background and Hypothesis In response to Health Canada’s March 2020 directive, patients on clozapine for over 12 months were allowed to extend hematological testing intervals from 4 to 8 weeks during the COVID-19 pandemic. We hypothesized that this change would not affect the timely detection of hematological abnormalities in patients with severe mental illness. Study Design A chart review was conducted of patients at the Royal Ottawa who were prescribed clozapine from March 2019 to March 2021. We analyzed clinical and hematological data from electronic health records and Clozaril Support and Assistance Network database to compare occurrences of hematological abnormalities [leukopenia (white blood cell count <3.5 × 109/L) and agranulocytosis (absolute neutrophil count <0.5 × 109/L)] from March 17, 2020 to March 16, 2021, between standard and extended monitoring protocols using binomial logistic and zero-inflated negative binomial regressions. Study Results Of 621 patients, 196 were on extended blood monitoring, and 425 followed standard blood monitoring. Clozapine dose did not differ between groups (standard: 370 ± 201 mg; extended: 352 ± 172 mg; P = .14, ds = 0.10). Clozapine treatment duration up to March 2021 was 12.6 ± 8.3 years, with the extended group (10 ± 7.9 years) having a significantly (P < .01, ds = 0.50) shorter duration than the standard (14 ± 8.2 years). Extended monitoring did not significantly impact likelihood of detecting hematological abnormalities (OR = 0.83, 95% CI [0.58,1.41], P = .55) after controlling for age, sex, total bloodwork, and other psychotropics associated with neutrophil counts (ie, valproate, olanzapine). No patient on the extended regimen developed agranulocytosis. Conclusions Reducing blood monitoring frequency in patients on clozapine for more than 12 months did not compromise detection of hematological abnormalities.

psychiatry
Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan

Maiko Watanabe,Fuminari Misawa,Hiroyoshi Takeuchi

DOI: https://doi.org/10.1097/jcp.0000000000001804

2024-01-27

Journal of Clinical Psychopharmacology

Abstract:Abstract Background Clozapine is considered the gold standard medication for treatment-resistant schizophrenia (TRS). However, given that clozapine treatment is associated with the burden of regular blood monitoring and the risk of life-threatening adverse effects, high-dose olanzapine can serve as an alternative treatment. We conducted a bidirectional mirror-image study to evaluate the effectiveness of high-dose olanzapine compared with clozapine. Methods We included patients with TRS who switched from olanzapine to clozapine or switched from clozapine to olanzapine, and received high-dose (>20 mg/d) olanzapine treatment for ≥4 weeks at Yamanashi Prefectural Kita Hospital. We obtained data on hospitalization, seclusion, and modified electroconvulsive therapy (mECT) during the clozapine phase and the olanzapine phase. Results A total of 44 patients were included. When patients switched from high-dose olanzapine to clozapine (n = 32), significant reductions were found in the total days of seclusion, the total number of mECT, and the number of patients who received mECT at least once. When patients switched from clozapine to high-dose olanzapine (n = 12), a significant reduction was found in the number of patients who received mECT at least once. When data from both directions of treatment were combined, significant reductions were found in the total days of seclusion, the total number of mECT, and the number of patients who received mECT at least once in favor of clozapine. Conclusions Findings suggest that high-dose olanzapine may not be as effective as clozapine for patients with TRS in real-world practice. However, it should be noted that there are unique circumstances that restrict the use of clozapine in Japan.

pharmacology & pharmacy,psychiatry
Drosophila beta 1,4-N-acetylgalactosaminyltransferase-A synthesizes the LacdiNAc structures on several glycoproteins and glycosphingolipids.

Norihiko Sasaki,H. Yoshida,Takashi J. Fuwa,A. Kinoshita-Toyoda,H. Toyoda,Y. Hirabayashi,H. Ishida,R. Ueda,S. Nishihara

DOI: https://doi.org/10.1016/J.BBRC.2007.01.015

2007-03-09

Abstract:
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?

Peter F J Schulte,Selene R T Veerman,Bert Bakker,Jan P A M Bogers,Amy Jongkind,Dan Cohen,Peter F.J. Schulte,Selene R.T. Veerman,Jan P.A.M. Bogers

DOI: https://doi.org/10.1016/j.schres.2023.09.024

IF: 4.662

2023-09-28

Schizophrenia Research

Abstract:After the introduction of clozapine eight Finnish patients died after developing agranulocytosis. Clozapine was withdrawn from the market and only reintroduced with strict mandatory white blood cell monitoring as long as treatment lasts and thresholds at which clozapine must be discontinued definitively. The fear of agranulocytosis and the need for intensive blood monitoring is the single most important barrier for prescribers and patients alike and leads to underprescription of the only effective and approved medication for treatment-resistant schizophrenia. We summarize evidence that the risk of agranulocytosis is smaller than perceived at the time of reintroduction, is concentrated in the first 18 weeks of treatment, is not greater than with other antipsychotics thereafter and that frequent blood monitoring has not demonstrably decreased the rate of agranulocytosis. Therefore we propose 1) mandatory monitoring of the absolute neutrophil count (ANC) exclusively during the first 18 weeks of clozapine treatment, 2) that thereafter the prescriber and the well-informed patient decide together about further monitoring frequency, 3) that clozapine treatment must be stopped if the ANC falls below 1.0 × 10 9 /L. Continuation of clozapine or a rechallenge are possible if prescriber and patient determine that the benefits outweigh the risks. 4) National registries which control the haematologic monitoring are unnecessary and do not help to reduce clozapine-induced agranulocytosis. They should at least be restricted to the first 18 weeks of clozapine use.

psychiatry
Hematological impact of COVID-19 mRNA vaccination in patients treated with Clozapine

A. Touiti,I. Yaich,C. Ben Said,N. Bram

DOI: https://doi.org/10.1192/j.eurpsy.2024.1070

2024-08-30

European Psychiatry

Abstract:Introduction Clozapine is an atypical antipsychotic that is primarily prescribed for treatment-resistant schizophrenia. Despite its proven efficacy, the prescription of clozapine is sometimes limited by its hematologic side effects, including agranulocytosis. During the SARS-CoV-2 pandemic, schizophrenia is recognized as a risk factor for developing severe forms of the infection. Early and complete vaccination of patients has been recommended. However, there is limited data on the effect of the vaccine on the risk of hematologic abnormalities in patients treated with clozapine. Objectives To study the hematologic effect of the mRNA vaccine against COVID-19 in a population of patients with treatment-resistant schizophrenia treated with clozapine. Methods Twenty-five patients hospitalized for schizophrenia at the forensic psychiatry department of Razi Hospital in Manouba, Tunisia, were included. Eighteen patients were treated with clozapine, and seven patients were treated with other antipsychotics. Consent from patients and/or their relatives was obtained before vaccination. The results of complete blood counts performed as part of the therapeutic protocol were compared between the two groups before and after administration of the vaccine. Results No patient experienced agranulocytosis induced by clozapine after vaccination against COVID-19.Blood cells counts,red blood cells counts,and platelets were within the normal ranges.However,a decrease in the number of WBCs,neutrophils,and lymphocytes was observed in patients treated with clozapine without significant difference compared to the patients treated with other neuroleptics, but there was no severe neutropenia or need to stop treatment. Conclusions The prescription of clozapine, the introduction protocol, and treatment administration have been greatly influenced by the COVID-19 pandemic due to the hepatotoxic risk of the drug. Vaccination is essential to prevent severe forms of the infection, especially in at-risk populations such as patients treated for schizophrenia.The potentiation of hematologic side effects induced by clozapine by the vaccine is not documented.The COVID-19 mRNA vaccine is safe even with clozapine Disclosure of Interest None Declared

psychiatry
Clozapine and the Risk of Severe COVID-19: A Retrospective Cohort Study

I. Yaich,A. Touiti,C. Ben Said,N. Bram

DOI: https://doi.org/10.1192/j.eurpsy.2024.558

2024-08-30

European Psychiatry

Abstract:Introduction Clozapine is the standard treatment for managing treatment-resistant schizophrenia (TRS). However, concerns arise due to potential hematologic side effects, such as agranulocytosis, especially during the COVID-19 pandemic. Objectives This study aims to investigate the association between clozapine treatment and an increased risk of severe COVID-19 infection in patients with TRS. Methods A retrospective study reviewed clinical records of forensic patients with TRS from 2020 to 2022 at Razi Hospital's forensic psychiatry department in Tunisia. Twenty-five patients, including 18 on clozapine treatment, were included. Results All patients were male, with an average age of 39.7 years. Twenty-three patients received at least one vaccine dose. Twenty-two patients contracted COVID-19. Among those treated with clozapine, two required intensive care unit admission and oxygen therapy without intubation. Clozapine treatment remained uninterrupted, with no dose escalation during infection episodes. Lymphopenia was the most commonly reported hematologic abnormality. Conclusions While there may be an association between clozapine use and an increased risk of COVID-19 infection, no clear correlation with infection severity and antipsychotic treatment was established in this study. Further research is needed to explore this potential association comprehensively. Disclosure of Interest None Declared

psychiatry
Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study

Ebenezer Oloyede,Christian J. Bachmann,Olubanke Dzahini,Juan Miguel Lopez Alcaraz,Shaurya Dev Singh,Kalliopi Vallianatu,Burkhardt Funk,Eromona Whiskey,David Taylor

DOI: https://doi.org/10.1192/bjp.2024.104

2024-08-19

The British Journal of Psychiatry

Abstract:Background Clozapine is the most effective antipsychotic for treatment-resistant psychosis. However, clozapine is underutilised in part because of potential agranulocytosis. Accumulating evidence indicates that below-threshold haematological readings in isolation are not diagnostic of life-threatening clozapine-induced agranulocytosis (CIA). Aims To examine the prevalence and timing of CIA using different diagnostic criteria and to explore demographic differences of CIA in patients registered on the UK Central Non-Rechallenge Database (CNRD). Method We analysed data of all patients registered on the UK Clozaril ® Patient Monitoring Service Central Non-Rechallenge Database (at least one absolute neutrophil count (ANC) < 1.5 × 10 9 /L and/or white blood cell count < 3.0 × 10 9 /L) between May 2000 and February 2021. We calculated prevalence rates of agranulocytosis using threshold-based and pattern-based criteria, stratified by demographic factors (gender, age and ethnicity). Differences in epidemiology based on rechallenge status and clozapine indication were explored. The proportion of patients who recorded agranulocytosis from a normal ANC was explored. Results Of the 3029 patients registered on the CNRD with 283 726 blood measurements, 593 (19.6%) were determined to have threshold-based agranulocytosis and 348 (11.4%) pattern-based agranulocytosis. In the total sample (75 533), the prevalence of threshold-based agranulocytosis and pattern-based agranulocytosis was 0.8% and 0.5%, respectively. The median time to threshold-based agranulocytosis was 32 weeks (IQR 184) and 15 (IQR 170) weeks for pattern-based agranulocytosis. Among age groups, the prevalence of pattern-based agranulocytosis and threshold-based agranulocytosis was highest in the >48 age group. Prevalence rates were greatest for White (18%) and male individuals (13%), and lowest for Black individuals (0.1%). The proportion of people who were determined to have pattern-based agranulocytosis without passing through neutropenia was 70%. Conclusions Threshold-based definition of agranulocytosis may over-diagnose CIA. Monitoring schemes should take into consideration neutrophil patterns to correctly identify clinically relevant CIA. In marked contrast to previous studies, CIA occurred least in Black individuals and most in White individuals.

psychiatry
Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study

Yuqi Hu,Le Gao,Lingyue Zhou,Wenlong Liu,Cuiling Wei,Boyan Liu,Qi Sun,Wenxin Tian,Rachel Yui Ki Chu,Song Song,Franco Wing Tak Cheng,Joe Kwun Nam Chan,Amy Pui Pui Ng,Heidi Ka Ying Lo,Krystal Chi Kei Lee,Wing Chung Chang,William Chi Wai Wong,Esther Wai Yin Chan,Ian Chi Kei Wong,Yi Chai,Francisco Tsz Tsun Lai

DOI: https://doi.org/10.1101/2024.08.07.24311592

2024-08-08

Abstract:Background: Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is unclear due to the absence of cohort studies. Methods: We extracted data from a territory-wide public healthcare database in Hong Kong to build a retrospective cohort of anonymized patients aged 18+ with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90+ days, with at least two prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between clozapine and olanzapine users. The absolute rate difference was also estimated. Results: In total, 9,965 patients were included, with 834 clozapine users, who had a significant IRR of 2.22 (95% CI 1.52, 3.34) for HM compared to olanzapine users. Absolute rate difference was estimated to be 57.40 (95% CI 33.24, 81.55) per 100,000 person-years. Findings were consistent across sub-groups by age and sex in terms of effect size, although the IRR was non-significant for those aged 65 or older. Sensitivity analyses all supported the robustness of the results and showed good specificity to HM but no other cancers. Conclusion: Absolute rate difference in HM incidence was very small although there is a twofold elevated rate. Pharmacotherapies with clozapine may consider this potential rare risk in addition to known side effects.

Psychiatry and Clinical Psychology
Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

Matthew Nuebel,Jonathan G Leung,Christopher Hughes,Ian McGrane

DOI: https://doi.org/10.9740/mhc.2024.06.204

2024-06-03

Abstract:Introduction: Clozapine is the only antipsychotic approved for treatment-resistant schizophrenia, but without appropriate monitoring, it can be associated with potentially fatal outcomes. An International Adult Clozapine Titration Guideline categorizes patients into normal or slow metabolizers. Categorization provides clozapine titration schedules and recommends regular c-reactive protein (CRP) and clozapine concentration monitoring to reduce the risk of adverse drug reactions (ADRs). The impact of the guideline on clozapine ADRs has not been evaluated. Methods: A retrospective chart review assessed clozapine titrations, laboratory monitoring, ADRs, and discontinuations for clozapine-naive adult inpatients at a single center from January 1, 2013, to June 1, 2022. Each patient's cumulative weekly clozapine dosage was compared with their guideline recommended dosage to create a percent accordance. Linear logistic regression evaluated the relationship between titration speed and the presence of an ADR, while descriptive statistics analyzed laboratory monitoring. Results: Forty-three patients were included, with the majority being White males with schizophrenia. An inverse relationship existed between the last inpatient week clozapine dose percent accordance and the probability of an ADR. Nonobese patients were less likely than obese patients to experience an ADR (odds ratio = 0.17; 95% CI, 0.03-0.99). CRP and clozapine concentration monitoring was suboptimal. Discussion: Based on our small retrospective review of primarily White males, more aggressive clozapine titrations did not increase ADRs. Future studies with more diverse samples are needed and should focus on specific ADRs, which may have increased occurrence with rapid titrations. Obese patients were at higher risk of ADRs, correlating with the guideline-recommended slower titrations for these patients.
Clozapine is associated with secondary antibody deficiency

Mark Ponsford,Daniel Castle,Tayyeb Tahir,Rebecca Robinson,Wendy Wade,Rachael Steven,Kathryn Bramhall,Mo Moody,Emily Carne,Catherine Ford,Daniel Farewell,Paul Williams,Tariq El-Shanawany,Stephen Jolles

DOI: https://doi.org/10.1192/bjp.2018.152

2018-09-12

The British Journal of Psychiatry

Abstract:Background Schizophrenia affects 1% of the population. Clozapine is the only medication licensed for treatment-resistant schizophrenia and is intensively monitored to prevent harm from neutropenia. Clozapine is also associated with increased risk of pneumonia although the mechanism is poorly understood. Aims To investigate the potential association between clozapine and antibody deficiency. Methods Patients taking clozapine and patients who were clozapine-naive and receiving alternative antipsychotics were recruited and completed a lifestyle, medication and infection-burden questionnaire. Serum total immunoglobulins (immunoglobulin (Ig)G, IgA, IgM) and specific IgG antibodies to haemophilus influenzae type B, tetanus and IgG, IgA and IgM to pneumococcus were measured. Results Immunoglobulins were all significantly reduced in the clozapine-treated group ( n = 123) compared with the clozapine-naive group ( n = 111). Odds ratios (ORs) for a reduction in clozapine:control immunoglobulin values below the fifth percentile were IgG, OR = 6.00 (95% CI 1.31–27.44); IgA, OR = 16.75 (95% CI 2.18–128.60); and IgM, OR = 3.26 (95% CI 1.75–6.08). These findings remained significant despite exclusion of other potential causes of hypogammaglobulinaemia. In addition, duration on clozapine was associated with decline in IgG. A higher proportion of the clozapine-treated group reported taking more than five courses of antibiotics in the preceding year (5.3% ( n = 5) versus 1% ( n = 1). Conclusions Clozapine use was associated with significantly reduced immunoglobulin levels and an increased proportion of patients using more than five antibiotic courses in a year. Antibody testing is not included in existing clozapine monitoring programmes but may represent a mechanistic explanation and modifiable risk factor for the increased rates of pneumonia and sepsis-related mortality previously reported in this vulnerable cohort. Declaration of interest S.J. has received support from CSL Behring, Shire, LFB, Biotest, Binding Site, Sanofi, GSK, UCB Pharma, Grifols, BPL SOBI, Weatherden, Zarodex and Octapharma for projects, advisory boards, meetings, studies, speaker and clinical trials.
Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics

Seong Hoon Jeong,Mi Gyung Lee,Yong Sik Kim,In Won Chung

DOI: https://doi.org/10.1097/yic.0000000000000506

2024-01-22

International Clinical Psychopharmacology

Abstract:It was reported that patients who contracted COVID-19 while taking clozapine exhibited a distinct hematological response. However, the absence of control groups made it difficult to attribute it to clozapine. The changes in absolute neutrophil counts (ANCs) during the 4 weeks after COVID-19 infection were compared between the two groups of patients with severe mental illnesses (SMIs) (49 patients using clozapine and 54 using other antipsychotics) using generalized additive modeling. Although the pattern of a transient drop in ANC followed by gradual recovery could be demonstrated in both groups, it was more pronounced in the clozapine group ( P = 0.00025). Nevertheless, overall ANC remained at a higher level in the clozapine group. The results suggested potential interaction between clozapine and COVID-19 at the level of hematological dynamics. However, it did not necessarily indicate that such interaction is inevitably harmful or dangerous. It was more of a concern that some patients using other antipsychotics exhibited decreased ANC, which did not easily recover. Traditionally, clinicians have been concerned about the worsening of hematological side effects in clozapine patients after COVID-19 infection. However, the obtained result highlighted the necessity of hematological monitoring in patients using any type of antipsychotics for SMIs.

pharmacology & pharmacy,psychiatry
Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study

Hirotaka Kazama,Satoshi Nishina,Takeshi Seto

DOI: https://doi.org/10.1093/jjco/hyae047

IF: 2.925

2024-04-20

Japanese Journal of Clinical Oncology

Abstract:Abstract Objective Clofarabine is used to treat acute lymphoblastic leukaemia, but evidence of its safety and effectiveness in Japanese patients is limited. We evaluated the safety and effectiveness of clofarabine in patients with relapsed/refractory acute lymphoblastic leukaemia in real-world clinical practice in Japan. Methods An observational, multicenter, post-marketing, all-case surveillance was conducted for safety. Effectiveness analyses were conducted in patients aged ≤21 years and those treated with clofarabine monotherapy and combination therapy (clofarabine plus etoposide and cyclophosphamide). Results In the all-case survey, 260 of 264 registered patients were eligible for safety analysis. Among the 225 patients eligible for effectiveness analysis, 139 were aged ≤21 years. For monotherapy and combination therapy, 20/31 and 34/88 patients were eligible, respectively. In the all-case survey, the median age was 16.0 years, and 47.7% of patients were <15 years old. Adverse drug reaction incidence was 83.5% and the most common were hematologic toxicities. The best overall response rates in the population aged ≤21 years were complete remission, 29.7%; complete remission without platelet recovery, 7.3% and partial remission, 10.9%. The rest (52.2%) were classified as ineffective. The sum of complete remission, complete remission without platelet recovery and partial remission rates (effectiveness rate) was 47.8% (66/138 patients). The effectiveness rates in the monotherapy and combination therapy surveys were 10.0% (2/20 patients) and 58.8% (20/34 patients), respectively. Conclusions These post-marketing surveys provide real-world evidence of the safety and effectiveness of clofarabine regimens, including monotherapy and combination therapy in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia. The safety and effectiveness profiles were comparable with those of previous prospective studies.

oncology
Psychiatrists' views on clozapine prescribing in Ireland

A Grant,R McManus,H Belay,M Mahon,F Murad,B O' Donoghue,J Lally

DOI: https://doi.org/10.1017/ipm.2024.35

2024-10-02

Abstract:Introduction: Despite proven effectiveness in refractory schizophrenia, clozapine remains underutilised, and it is important to understand potential reasons for this. This study's aim was to examine in a National sample of Consultant Psychiatrists their knowledge of, attitudes and perceived barriers to clozapine use. Methods: A novel questionnaire was designed and distributed by email to 275 Consultant Psychiatrists in Republic of Ireland. Results: Twenty-eight percent (n = 77) completed the survey, with 55% of respondents practicing for 15 or more years. Clinicians expressed confidence in managing clozapine treatment and side effects and were well aware of clozapine's clinical effectiveness and guideline-based use. A majority indicated insufficient experience managing rechallenge and half expressed insufficient experience managing adverse events. Perceived patient factors were highlighted as barriers with 69% of respondents reporting patients' concern about effectiveness and 50% regarding tolerability. Sixty-four percent (n = 40) indicated that a specialised/tertiary clozapine service would facilitate initiation, with 57% (n = 36) reporting less frequent blood monitoring would aid clozapine prescribing. A majority identified that access to dedicated staff (81%, n = 51) and dedicated day hospital services (84%, n = 53) would facilitate community initiation. Conclusion: Consultants are familiar with clozapine use and related guidelines. Dedicated staff and facilities for clozapine use is one identified structural change to enhance clozapine prescribing in Ireland. Tertiary service or clinical advice service would assist in clozapine rechallenge cases or in managing significant adverse events. More structured patient education regarding clozapine effectiveness and professional development programmes focused on managing side effects and rechallenge may promote clozapine use.
Neurovascularization of the anterior jaw bones revisited using high-resolution magnetic resonance imaging.

R. Jacobs,I. Lambrichts,Xin Liang,W. Martens,N. Mraiwa,P. Adriaensens,J. Gelan

DOI: https://doi.org/10.1016/J.TRIPLEO.2006.11.014

2007-05-01

Abstract:
High vulnerability to adverse reactions to antipsychotics: A case report

Ying Qiao,Xinyi Cao,Jianhua Sheng

DOI: https://doi.org/10.3969/j.issn.1002-0829.2011.05.011

2011-01-01

Abstract:This patient had antipsychotic-induced extrapyramidal symptoms and leucopenia. We use both psychiatric and neurological approaches to managing these side effects. We adopted the neurological approach to treating the extrapyramidal side-effects when the psychiatric approach proved ineffective. In addition, we found that prior leukopenia is a relative-but not absolute-contraindication for using clozapine: patients with a prior history of leukopenia (but not agranulocytosis) can be carefully re-challenged with clozapine while their blood counts are being closely monitored. Copyright © 2011 by Editorial Department of Shanghai Archives of Psychiatry.
The Three Last Years of Manuel II Palaeologus’ Reign Between Two Stroke Attacks: Aphasia or Not?

D. Vassilopoulos,E. Poulakou‐Rebelakou,John V. Palaeologus

DOI: https://doi.org/10.1080/0964704X.2010.516683

2011-10-01

Journal of the History of the Neurosciences

Abstract:The authors attempt to solve the enigma about the possible aphasia of the Byzantine Emperor Manuel II Palaeologus (1391–1425) in the 3-year period between his first and his second and fatal stroke. The texts of historians and chroniclers reveal that Manuel remained semi-paralyzed at bed and his motor disability alienated him from the state affairs and condemned him to isolation from all embassies and contact with others, except his family. Only the funeral oration of the Bishop Bessarion raises the suspicion of a speechless emperor. All testimonies referring to this infirmity are examined.
Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis

Ronald J. Gurrera,Priya F. Gearin,Jonathan Love,Kevin J. Li,Ashley Xu,Faith H. Donaghey,Matthew R. Gerace

DOI: https://doi.org/10.1111/acps.13406

2022-03-16

Acta Psychiatrica Scandinavica

Abstract:OBJECTIVE: Clozapine is substantially underutilized in most countries and clinician factors including lack of knowledge and concerns about adverse drug effects (ADEs) contribute strongly to treatment reluctance. The aim of this systematic review was to provide clinicians with a comprehensive information source regarding clozapine ADEs.METHODS: PubMed and Embase databases were searched for English language reviews concerned with clozapine ADEs; publications identified by the automated search were manually searched for additional relevant citations. Following exclusion of redundant and irrelevant reports, pertinent information was summarized in evidence tables corresponding to each of six major ADE domains; two authors reviewed all citations for each ADE domain and summarized their content by consensus in the corresponding evidence table. This study was conducted in accordance with PRISMA principles.RESULTS: Primary and secondary searches identified a total of 305 unique reports, of which 152 were included in the qualitative synthesis. Most clozapine ADEs emerge within 3 months, and almost all appear within 6 months, after initiation. Notable exceptions are weight gain, diabetic ketoacidosis (DKA), severe clozapine-induced gastrointestinal hypomotility (CIGH), clozapine-induced cardiomyopathy (CICM), seizures, and clozapine-induced neutropenia (CIN). Most clozapine ADEs subside gradually or respond to dose reduction; those that prompt discontinuation generally do not preclude rechallenge. Rechallenge is generally inadvisable for clozapine-induced myocarditis (CIM), CICM, and clozapine-induced agranulocytosis (CIA). Clozapine plasma levels >600-1000 μg/L appear more likely to cause certain ADEs (e.g., seizures) and, although there is no clear toxicity threshold, risk/benefit ratios are generally unfavorable above 1000 μg/L.CONCLUSION: Clozapine ADEs rarely require discontinuation.

psychiatry
Infant social attachments: a reinforcement theory interpretation and investigation.

R. Wahler

DOI: https://doi.org/10.1111/J.1467-8624.1967.TB04383.X

IF: 5.661

1967-12-01

Child Development

Abstract:The responsiveness of 3-month-old infants to their mothers and to female strangers was evaluated. Attempts were made to condition instrumentally the smiling behavior of 13 infants, using their mothers and female strangers as dispensers of s6cial reinfrocement. The results indicated that the mothers were more effective than the strangers in obtaining reinforcement control of the smiling behavior.

Metastatic choriocarcinoma during normal pregnancy presenting as thyroid tumor

From strict quarantine to an optimized policy: Are we psychologically prepared?

Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine

Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic

Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan

Drosophila beta 1,4-N-acetylgalactosaminyltransferase-A synthesizes the LacdiNAc structures on several glycoproteins and glycosphingolipids.

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?

Hematological impact of COVID-19 mRNA vaccination in patients treated with Clozapine

Clozapine and the Risk of Severe COVID-19: A Retrospective Cohort Study

Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study

Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study

Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

Clozapine is associated with secondary antibody deficiency

Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics

Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study

Psychiatrists' views on clozapine prescribing in Ireland

Neurovascularization of the anterior jaw bones revisited using high-resolution magnetic resonance imaging.

High vulnerability to adverse reactions to antipsychotics: A case report

The Three Last Years of Manuel II Palaeologus’ Reign Between Two Stroke Attacks: Aphasia or Not?

Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis

Infant social attachments: a reinforcement theory interpretation and investigation.